Published on Novartis (https://www.novartis.com)
Home > Printer-friendly PDF > Event Calendar
Event Calendar
View recent presentations and learn more about upcoming events.
Disclaimer:
Disclaimer: The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only. Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.
Tab:
Upcoming Events
Third quarter results 2021
Oct 26, 2021 Basel, Switzerland
Recent Events [1]
ESG Investor Day
Sep 30, 2021
Watch the webcast [2]
Download the podcast (MP3 66 MB) [3] Access our interactive slide deck (PDF 9.6 MB) [4]
Read the media release [5]
Novartis ESG Investor Day 2021 6 key takeaways [6]
Bernstein Strategic Decisions Conference
Sep 23, 2021
Baader Investment Conference
Sep 21, 2021
Bank of America Merrill Lynch Global Healthcare Virtual Conference
Sep 15, 2021
Morgan Stanley Global Healthcare Conference
Sep 13, 2021
Citi's GEMS Virtual Conference 2021
Sep 8, 2021
Second quarter results 2021
Jul 21, 2021 Basel, Switzerland
Media release
English (PDF 0.4 MB) [7] Deutsch (PDF 0.4 MB) [8] Français (PDF 0.4 MB) [9]
Interim financial report (PDF 0.5 MB) [10]
Watch the webcast [11]
Read the presentation transcript [12] Download the podcast (MP3 45 MB) [13]
Download the interactive presentation (PDF 4.5 MB) [14]
Novartis ESG Update - July 22, 2021 (PDF 1.8 MB) [15]
Guggenheim Biopharma's Next Decade
Jun 23, 2021
Iptacopan (LNP023) update
Jun 22, 2021
Watch the webcast [16]
Download the podcast (MP3 40 MB) [17]
Download the presentation (PDF 2.2 MB) [18]
dbAccess Conference
Jun 16-17, 2021
Berlin, Germany
Citi European Healthcare Conference
Jun 15, 2021
Goldman Sachs Conference
Jun 09-10, 2021
Oncology update
Jun 08, 2021
Watch the webcast [19]
Download the presentation (PDF 2.5 MB) [20]
Bernstein Annual Strategic Decisions Jun 04, 2021
Jefferies Healthcare Conference
Jun 03, 2021
Webinar: Materiality and impact valuation as key enablers of corporate purpose
Jun 01, 2021
Register for the event [21]
UBS Global Healthcare Conference
May 24, 2021
Berenberg Conference
May 18, 2021
Cardiovascular update
May 18, 2021
Watch the webcast [22]
Download the presentation (PDF 3.6 MB) [23]
Download the podcast (MP3 43 MB) [24]
Bank of America ML Healthcare Conference
May 11, 2021
First quarter results 2021
Apr 27, 2021 Basel, Switzerland
Media release
English (PDF 0.2 MB) [25] Deutsch (PDF 0.2 MB) [26] Français (PDF 0.2 MB) [27]
Interim financial report (PDF 0.4 MB) [28]
Watch the webcast [29]
Read the presentation transcript [30]
Download the podcast (MP3 40 MB) [31]
Download the interactive presentation (PDF 7.2 MB) [32]
Novartis ESG Update - April 28, 2021 (PDF 0.3 MB) [33]
Guggenheim Protein Degradation Day
Mar 16, 2021
Barclays Healthcare Conference
Mar 09, 2021
Annual General Meeting
Mar 02, 2021 Basel, Switzerland
Visit the Annual General Meeting section [34]
Cowen Healthcare Conference
Mar 01, 2021
Leerink Global Healthcare Conference
Feb 25, 2021
Watch the webcast [35]
Entresto® FDA Label Expansion Investor Q&A Call Feb 17, 2021 Basel, Switzerland
Watch the webcast [36]
Download the podcast (MP3 22 MB) [37]
Download the presentation (PDF 0.6 MB) [38]
Citi Immuno-Oncology Conference
Feb 17, 2021
Guggenheim Healthcare Talks | Oncology Day
Feb 11, 2021
Materiality Assessment Webinar: Dialogue matters – support us to spur positive impact
Feb 08, 2021
Watch the webcast [39]
Download the presentation (PDF 3.3 MB) [40]
Fourth Quarter and Full Year Results 2020 and Annual Report 2020 publication
Jan 26, 2021 Basel, Switzerland
Media release:
English (PDF 0.2 MB) [41] Deutsch (PDF 0.2 MB) [42] Français (PDF 0.2 MB) [43]
Condensed financial report (PDF 0.9 MB) [44]
Watch the webcast [45]
Read the presentation transcript [46]
Download the podcast (MP3 45 MB) [47] Download the presentation (PDF 5.6 MB) [48]
Access our interactive slide deck (PDF 12 MB) [49]
Novartis ESG Update - January 27, 2021 (PDF 0.5 MB) [50]
Download the Annual Report 2020 (PDF 3.5 MB) [51]
Visit the Novartis Annual Reporting Suite section [52]
J.P. Morgan Healthcare Conference
Jan 11, 2021 Virtual / San Francisco, USA
Listen to the webcast [53]
Download the presentation (PDF 1.0 MB) [54]
2020 Archive [55]
Co-Creating Impact Summit
Dec 09, 2020
Register for the event [56]
Download the agenda (PDF 0.1 MB) [57]
Société Générale Premium Review Conference
Dec 02, 2020 Virtual / Paris, France
Berenberg European Conference
Dec 02, 2020 Virtual / London, UK
Redburn CEO Conference
Dec 01, 2020 Virtual / London, UK
Meet Novartis Management
Nov 24, 2020
Download the agenda (PDF 0.1 MB) [58]
Visit the Event Center [59]
UBS European Conference
Nov 11, 2020 London, UK
Inaugural Healthcare CEO Summit
Nov 05, 2020 Baltimore, USA
Webinar: Measuring and evaluating social outcomes of access initiatives
Oct 28, 2020
Register for the event [60]
Third quarter results 2020
Oct 27, 2020 Basel, Switzerland
Media release
English (PDF 0.2 MB) [61] Deutsch (PDF 0.2 MB) [62] Français (PDF 0.3 MB) [63]
Interim financial report (PDF 0.8 MB) [64]
Watch the webcast [65]
Read the presentation transcript [66]
Download the podcast (MP3 41 MB) [67] Download the presentation (PDF 2.7 MB) [68]
Novartis ESG Update - October 28, 2020 (PDF 0.5 MB) [69]
Bank of America Merrill Lynch Global Healthcare Conference
Sep 18, 2020 London, UK
Novartis ESG Investor Event
Sep 01, 2020
Download the presentation (PDF 3.2 MB) [70]
Read the media release [71]
Kesimpta® FDA Approval Investor Call
Aug 21, 2020 Basel, Switzerland
Download the podcast (MP3 28 MB) [72]
Download the presentation (PDF 1.0 MB) [73]
ESG materiality assessment webinar: Wealth and Health - Reframing healthcare costs as economic investments
Jul 30, 2020
Register for the event [74]
Second quarter results 2020
Jul 21, 2020 Basel, Switzerland
Media release
English (PDF 0.2 MB) [75] Deutsch (PDF 0.2 MB) [76] Français (PDF 0.3 MB) [77] Interim financial report (PDF 0.8 MB) [78]
Read the presentation transcript [79]
Download the podcast (MP3 44 MB) [80]
Download the presentation (PDF 2.6 MB) [81]
Novartis ESG Update - July 24, 2020 (PDF 0.6 MB) [82]
ESG materiality assessment webinar: Embracing double materiality in responding to the COVID-19 pandemic
Jun 25, 2020
Register for the event [83]
JP Morgan European Healthcare Conference
Jun 18, 2020 London, UK
Citi European Healthcare Conference
Jun 17, 2020 London, UK
Oncology Pipeline Update
Jun 15, 2020 Basel, Switzerland
Download the podcast (MP3 44 MB) [84]
Download the presentation (PDF 3.3 MB) [85]
ESG materiality assessment webinar: sickle cell disease
May 28, 2020
Register for the event [86]
UBS Virtual Global Healthcare Conference May 19-20, 2020
First quarter results 2020
Apr 28, 2020 Basel, Switzerland
Media release
English (PDF 0.2 MB) [87] Deutsch (PDF 0.2 MB) [88] Français (PDF 0.2 MB) [89]
Interim financial report (PDF 0.6 MB) [90]
Read the presentation transcript [91]
Download the podcast (MP3 45 MB) [92]
Download the presentation (PDF 3.0 MB) [93]
Novartis ESG Update – April 29, 2020 [94]
Zolgensma® MDA Data Investor Call
Mar 30, 2020 Basel, Switzerland
Download the podcast (MP3 30 MB) [95]
Download the presentation (PDF 1.1 MB) [96]
Bernstein DCAT
Mar 25, 2020 New York, USA
Cowen Healthcare Conference
Mar 04, 2019 Boston, USA
Annual General Meeting Feb 28, 2020 Basel, Switzerland
Visit the Annual General Meeting section [34]
Leerink Global Healthcare Conference
Feb 27, 2020 New York, USA
Guggenheim Healthcare Talks
Feb 13, 2020 New York, USA
Fourth Quarter and Full Year Results 2019 and Annual Report 2019 publication
Jan 29, 2020 Basel, Switzerland
Media release:
English (PDF 0.1 MB) [97] Deutsch (PDF 0.1 MB) [98] Français (PDF 0.2 MB) [99]
Condensed financial report (PDF 0.6 MB) [100]
Read the presentation transcript [101]
Download the podcast (MP3 43 MB) [102]
Download the presentation (PDF 3.6 MB) [103]
Download the Annual Report 2019 (PDF 4 MB) [104]
Visit the Novartis Annual Reporting Suite section [52]
J.P. Morgan Healthcare Conference
Jan 13, 2020 San Francisco, USA
Read the transcript [105] Download the presentation podcast (MP3 10 MB) [106]
Download the Q&A podcast (MP3 12 MB) [107]
Download the presentation (PDF 1.4 MB) [108]
2019 Archive [109]
Citi Healthcare Conference
Dec 11, 2019 New York, USA
R&D Day
Dec 05, 2019 London, UK
Read the media release [110]
Download the agenda (PDF 0.1 MB) [111]
Download the presentation (PDF 8.1 MB) [112]
Berenberg European Corporate Conference
Dec 04, 2019 London, UK
Novartis enters into agreement to acquire The Medicines Company
Nov 25, 2019 Basel, Switzerland
Read the media release [113]
Read the presentation transcript [114]
Download the podcast (MP3 26 MB) [115]
Download the presentation (PDF 0.6 MB) [116] Jefferies LondonNov 20, 2019 HealthcareLondon, UK Conference UBS European Conference
Nov 12, 2019 London, UK
Wolfe Healthcare Conference
Nov 06, 2019 New York, USA
ZKB Swiss Conference
Nov 06, 2019 Zurich, Switzerland
Third quarter results 2019
Oct 22, 2019 Basel, Switzerland
Media release
English (PDF 0.1 MB) [117] Deutsch (PDF 0.2 MB) [118] Français (PDF 0.3 MB) [119]
Interim financial report (PDF 0.8 MB) [120]
Read the presentation transcript [121]
Download the presentation (PDF 2.3 MB) [122]
Beovu® FDA Approval
Oct 08, 2019 Basel, Switzerland Read the media release [123]
Download the presentation (PDF 1.4 MB) [124]
Download the podcast (MP3 22 MB) [125]
Kisqali® MONALEESA-3 ESMO Data Investor Call
Oct 01, 2019 Basel, Switzerland
Download the podcast (MP3 14 MB) [126]
Download the presentation (PDF 1.8 MB) [127]
Bernstein’s Strategic Decisions Conference
Sep 26, 2019 London, UK
Baader Investment Conference
Sep 24, 2019 Munich, Germany
Bank of America Merrill Lynch Global Healthcare Conference
Sep 18, 2019 London, UK
Ofatumumab (OMB157) ECTRIMS Data Investor Call
Sep 16, 2019 Basel, Switzerland
Download the podcast (MP3 26 MB) [128]
Download the presentation (PDF 1.1 MB) [129]
ESG Investor Event Sep 09, 2019 London, UK
Download the podcast (MP3 40 MB) [130]
Download the presentation (PDF 4.8 MB) [131]
UBS Best of Switzerland Conference 2019
Sep 05-06, 2019 Zurich, Switzerland
Zolgensma® Update
Aug 07, 2019
Read the media release (PDF 0.4 MB) [132]
Download the podcast (MP3 16 MB) [133]
Second quarter results 2019
July 18, 2019 Basel, Switzerland
Media release
English (PDF 0.1 MB) [134] Deutsch (PDF 0.1 MB) [135] Français (PDF 0.2 MB) [136]
Interim financial report (PDF 0.6 MB) [137]
Read the presentation transcript [138]
Download the podcast (MP3 41 MB) [139]
Download the presentation (PDF 2.2 MB) [140]
JP Morgan European Healthcare Conference
Jun 20, 2019 London, UK Citi EuropeanJun 19, 2019 HealthcareLondon, UK Conference Wolfe Research Pipelines Unplugged
Jun 05, 2019 New York, USA
Vontobel Summer Conference
Jun 05, 2019 Interlaken, Switzerland
Jefferies Global Healthcare Conference
Jun 04, 2019 New York, USA
ASCO Investor Event
Jun 02, 2019 Chicago, USA
Download the presentation (PDF 0.8 MB) [141]
UBS Best of Europe Conference
May 29, 2019 New York, USA
Zolgensma® and Piqray® US FDA Approvals
May 27, 2019
Read the media releases:
AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA) [142] AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families [143]
Zolgensma US Prescribing Information (PDF 0.3 MB) [144]
FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer [145]
Download the presentation (PDF 0.8 MB) [146]
Download the podcast (MP3 22 MB) [147]
Meet Novartis Management investor event in Boston
May 23, 2019 Boston, USA
Read the media release [148]
Download the presentation (PDF 7.8 MB) [149]
Download the agenda (PDF 0.1 MB) [150]
Novartis enters into agreement to acquire Xiidra®
May 09, 2019
Read the media release [151]
Download the podcast (MP3 18 MB) [152]
Download the presentation (PDF 0.8 MB) [153]
Zolgensma AAN Data Investor Call
May 08, 2019 Philadelphia, USA
Download the podcast (MP3 25 MB) [154]
Download the presentation (PDF 1.0 MB) [155] First quarterApr 24, 2019 resultsBasel, Switzerland 2019
Media release
English (PDF 0.5 MB) [156] Deutsch (PDF 0.4 MB) [157] Français (PDF 0.8 MB) [158]
Interim financial report (PDF 0.5 MB) [159]
Read the presentation transcript [160]
Download the podcast (MP3 41 MB) [161]
Download the presentation (PDF 1.4 MB) [162]
2017/2018 Results for Continuing Operations
Apr 24, 2019
Download the presentation (PDF 0.4 MB) [163]
Mayzent FDA Approval Investor Call
Mar 27, 2019 Basel, Switzerland
Read the media release [164]
Download the presentation (PDF 0.9 MB) [165]
Download the podcast (MP3 23 MB) [166]
Updated Alcon 20-F filed with the SEC
Mar 22, 2019
Download the updated Alcon 20-F (PDF 2.0 MB) [167]
SEC filing [168] Kepler Cheuvreux Swiss Seminar
Mar 21, 2019 Zurich, Switzerland
Bernstein DCAT Day
Mar 18, 2019 New York, USA
Barclays Global Healthcare Conference
Mar 12, 2019 Miami, USA
Cowen Healthcare Conference
Mar 11, 2019 Boston, USA
Credit Suisse Global Healthcare Conference
Mar 06, 2019 London, UK
Leerink Global Healthcare Conference
Mar 01, 2019 New York, USA
Annual General Meeting
Feb 28, 2019 Basel, Switzerland
Visit the Annual General Meeting section [34]
Citi's 7th Annual IO Leadership Summit
Feb 19, 2019 New York, USA Guggenheim PartnersFeb 14, 2019 OncologyNew York, USA Day Fourth Quarter and Full Year Results 2018 and Annual Report 2018 publication
Jan 30, 2019 Basel, Switzerland
Media release:
English (PDF 0.1 MB) [169] Deutsch (PDF 0.1 MB) [170] Français (PDF 0.2 MB) [171]
Condensed financial report (PDF 0.6 MB) [172]
Read the presentation transcript [173]
Download the podcast (MP3 51 MB) [174]
Download the presentation (PDF 3.4 MB) [175]
Download the Annual Report 2018 (PDF 3.8 MB) [176]
J.P. Morgan Healthcare Conference
Jan 07, 2019 San Francisco, USA
Download the presentation (PDF 1.9 MB) [177]
2018 Archive [178]
Citi Healthcare Conference
Dec 05, 2018 New York, USA
Berenberg European Corporate Conference Dec 05, 2018 London, UK
Alcon capital markets day in London
Dec 04, 2018 London, UK
Download the agenda (PDF 0.1 MB) [179]
Download the presentation (PDF 5.9 MB) [180]
Alcon capital markets day in New York
Nov 27, 2018 New York, USA
Read the media release [181]
Download the agenda (PDF 0.1 MB) [179]
Download the presentation (PDF 5.9 MB) [182]
Jefferies London Healthcare Conference
Nov 14, 2018 London, UK
UBS European Conference
Nov 13, 2018 London, UK
SG European ESG/SRI Conference Paris
Nov 13, 2018 Paris, France
Credit Suisse Healthcare Conference
Nov 12-13, 2018 Phoenix, USA
HSBC Healthcare Day
Nov 12, 2018 Frankfurt, Germany
Morningstar's Management Behind the Moat Conference
Nov 07-08, 2018 Chicago, USA
Restatement for the Innovative Medicines and Alcon Segments 2015 and 2016 following the OTC Transfer
Nov 07, 2018
Download the presentation (PDF 0.2 MB) [183]
Novartis R&D update
Nov 05, 2018 London, UK
Read the media release [184]
Download the agenda (PDF 0.1 MB) [185]
Download the presentation (PDF 5.6 MB) [186]
ESMO Investor Call
Oct 22, 2018
Download the podcast (MP3 5.1 MB) [187]
Download the presentation (PDF 0.9 MB) [188]
Third quarter results 2018
Oct 18, 2018 Basel, Switzerland Media release
English (PDF 0.1 MB) [189] Deutsch (PDF 0.1 MB) [190] Français (PDF 0.2 MB) [191]
Interim financial report (PDF 0.7 MB) [192]
Read the presentation transcript [193]
Download the podcast (MP3 38 MB) [194]
Download the presentation (PDF 1.8 MB) [195]
Source URL: https://www.novartis.com/investors/event-calendar
Links [1] https://www.novartis.com/investors/event-calendar#tab-2 [2] https://onlinexperiences.com/Launch/QReg/ShowUUID=31827FFF-26CE-40D7-9594- 755B78163C9A&LangLocaleID=1033 [3] https://www.novartis.com/sites/www.novartis.com/files/2021-09-novartis-esg-day-presentation.mp3 [4] https://www.novartis.com/sites/www.novartis.com/files/2021-09-novartis-esg-day-presentation.pdf [5] https://www.novartis.com/news/media-releases/novartis-accelerates-efforts-toward-esg-targets- increase-access-medicines-improve-health-equity-and-achieve-net-zero-carbon-emissions [6] https://www.youtube.com/watch?v=1SAjEYdky5k [7] https://www.novartis.com/sites/www.novartis.com/files/q2-2021-media-release-en.pdf [8] https://www.novartis.com/sites/www.novartis.com/files/q2-2021-media-release-de.pdf [9] https://www.novartis.com/sites/www.novartis.com/files/q2-2021-media-release-fr.pdf [10] https://www.novartis.com/sites/www.novartis.com/files/2021-07-interim-financial-report-en.pdf [11] https://edge.media-server.com/mmc/p/t6hj2xsz [12] https://www.novartis.com/investors/financial-data/quarterly-results/2021-q2-transcript [13] https://www.novartis.com/sites/www.novartis.com/files/q2-2021-investor-presentation.mp3 [14] https://www.novartis.com/sites/www.novartis.com/files/q2-2021-investor-presentation.pdf [15] https://www.novartis.com/sites/www.novartis.com/files/environmental-social-and-governance-july- 2021-update.pdf [16] https://onlinexperiences.com/Launch/QReg/ShowUUID=B4208415-ECFC-4F0D-8E83- 3921EA57A562&LangLocaleID=1033 [17] https://www.novartis.com/sites/www.novartis.com/files/2021_iptacopan-lnp023-update- presentation.mp3 [18] https://www.novartis.com/sites/www.novartis.com/files/2021_iptacopan-lnp023-update- presentation.pdf [19] https://onlinexperiences.com/Launch/QReg/ShowUUID=A07ADD67-5A5E-402A-83DF- 9635E7DC9742&LangLocaleID=1033 [20] https://www.novartis.com/sites/www.novartis.com/files/2021-06-novartis-asco-call-presentation.pdf [21] https://survey.alchemer.eu/s3/90325786/Registration-Materiality-Assessment-Webinar-1-June-2021 [22] https://edge.media-server.com/mmc/p/ikivbyzp [23] https://www.novartis.com/sites/www.novartis.com/files/novartis-may-2021-cardiovascular-update.pdf [24] https://www.novartis.com/sites/www.novartis.com/files/novartis-cardiovascular-update.mp3 [25] https://www.novartis.com/sites/www.novartis.com/files/q1-2021-media-release-en.pdf [26] https://www.novartis.com/sites/www.novartis.com/files/q1-2021-media-release-de.pdf [27] https://www.novartis.com/sites/www.novartis.com/files/q1-2021-media-release-fr.pdf [28] https://www.novartis.com/sites/www.novartis.com/files/2021-04-interim-financial-report-en.pdf [29] https://edge.media-server.com/mmc/p/8htwmdkn [30] https://www.novartis.com/investors/financial-data/quarterly-results/2021-q1-transcript [31] https://www.novartis.com/sites/www.novartis.com/files/q1-2021-investor-presentation.mp3 [32] https://www.novartis.com/sites/www.novartis.com/files/q1-2021-investor-presentation.pdf [33] https://www.novartis.com/sites/www.novartis.com/files/environmental-social-and-governance-apr- 2021-update.pdf [34] https://www.novartis.com/investors/shareholder-information/annual-general-meeting [35] https://wsw.com/webcast/svbleerink47/nvs/2471936 [36] https://edge.media-server.com/mmc/p/5tu3izry [37] https://www.novartis.com/sites/www.novartis.com/files/novartis-2021-entresto-label-update- presentation.mp3 [38] https://www.novartis.com/sites/www.novartis.com/files/novartis-2021-entresto-label-update- presentation.pdf [39] http://www.kaltura.com/tiny/wjead [40] https://www.novartis.com/sites/www.novartis.com/files/novartis-materiality-assessment-2021-kickoff- webinar-presentation.pdf [41] https://www.novartis.com/sites/www.novartis.com/files/q4-2020-media-release-en.pdf [42] https://www.novartis.com/sites/www.novartis.com/files/q4-2020-media-release-de.pdf [43] https://www.novartis.com/sites/www.novartis.com/files/q4-2020-media-release-fr.pdf [44] https://www.novartis.com/sites/www.novartis.com/files/2021-01-interim-financial-report-en.pdf [45] https://edge.media-server.com/mmc/p/g655yyy5 [46] https://www.novartis.com/investors/financial-data/quarterly-results/2020-q4-and-full-year-results- transcript [47] https://www.novartis.com/sites/www.novartis.com/files/q4-2020-investor-presentation.mp3 [48] https://www.novartis.com/sites/www.novartis.com/files/q4-2020-investor-presentation.pdf [49] https://www.novartis.com/sites/www.novartis.com/files/q4-2020-investor-interactive-deck.pdf [50] https://www.novartis.com/sites/www.novartis.com/files/environmental-social-and-governance-january- 2021-update.pdf [51] https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2020.pdf [52] https://www.novartis.com/investors/novartis-annual-reporting-suite [53] https://jpmorgan.metameetings.net/events/healthcare21/sessions/35412- novartis/webcast?gpu_only=true&kiosk=true [54] https://www.novartis.com/sites/www.novartis.com/files/2021-novartis-vas-narasimhan-jpmorgan- presentation.pdf [55] https://www.novartis.com/investors/event-calendar#tab-3 [56] https://www.surveygizmo.eu/s3/90283352/Registration-CCI-Summit-Dec9 [57] https://www.novartis.com/sites/www.novartis.com/files/agenda-co-creating-impact-summit-dec- 2020.pdf [58] https://www.novartis.com/sites/www.novartis.com/files/2020-10-mnm-agenda.pdf [59] https://www.novartis.com/investors/event-calendar/meet-novartis-management [60] https://www.surveygizmo.eu/s3/90277055/Registration-MA-Webinar-Measuring-and-Evaluating- Social-Outcomes-of-Access-Initiatives [61] https://www.novartis.com/sites/www.novartis.com/files/q3-2020-media-release-en.pdf [62] https://www.novartis.com/sites/www.novartis.com/files/q3-2020-media-release-de.pdf [63] https://www.novartis.com/sites/www.novartis.com/files/q3-2020-media-release-fr.pdf [64] https://www.novartis.com/sites/www.novartis.com/files/2020-10-interim-financial-report-en.pdf [65] https://edge.media-server.com/mmc/p/3soac2di [66] https://www.novartis.com/investors/financial-data/quarterly-results/2020-q3-transcript [67] https://www.novartis.com/sites/www.novartis.com/files/q3-2020-investor-presentation.mp3 [68] https://www.novartis.com/sites/www.novartis.com/files/q3-2020-investor-presentation.pdf [69] https://www.novartis.com/sites/www.novartis.com/files/environmental-social-and-governance-october- 2020-update.pdf [70] https://www.novartis.com/sites/www.novartis.com/files/2020-09-novartis-esg-day-presentation.pdf [71] https://www.novartis.com/news/media-releases/novartis-announces-ambitious-esg-targets-increase- access-medicines-and-achieve-full-carbon-neutrality [72] https://www.novartis.com/sites/www.novartis.com/files/2020-08-kesimpta-us-approval-investor-call- presentation.mp3 [73] https://www.novartis.com/sites/www.novartis.com/files/2020-08-kesimpta-us-approval-investor-call- presentation.pdf [74] https://www.surveygizmo.eu/s3/90251566/Registration-MA-Webinar-Health-is-Wealth [75] https://www.novartis.com/sites/www.novartis.com/files/q2-2020-media-release-en.pdf [76] https://www.novartis.com/sites/www.novartis.com/files/q2-2020-media-release-de.pdf [77] https://www.novartis.com/sites/www.novartis.com/files/q2-2020-media-release-fr.pdf [78] https://www.novartis.com/sites/www.novartis.com/files/2020-07-interim-financial-report-en.pdf [79] https://www.novartis.com/investors/financial-data/quarterly-results/2020-q2-transcript [80] https://www.novartis.com/sites/www.novartis.com/files/q2-2020-investor-presentation.mp3 [81] https://www.novartis.com/sites/www.novartis.com/files/q2-2020-investor-presentation.pdf [82] https://www.novartis.com/sites/www.novartis.com/files/environmental-social-and-governance-july- 2020-update.pdf [83] https://www.surveygizmo.eu/s3/90244617/Registration-MA-Webinar-Embracing-double-materiality [84] https://www.novartis.com/sites/www.novartis.com/files/2020-06-novartis-oncology-pipeline-update- presentation.mp3 [85] https://www.novartis.com/sites/www.novartis.com/files/2020-06-novartis-oncology-pipeline-update- presentation.pdf [86] https://www.surveygizmo.eu/s3/90236163/Registration-MA-Webinar-Rethinking-Healthcare-System- Strengthening [87] https://www.novartis.com/sites/www.novartis.com/files/q1-2020-media-release-en.pdf [88] https://www.novartis.com/sites/www.novartis.com/files/q1-2020-media-release-de.pdf [89] https://www.novartis.com/sites/www.novartis.com/files/q1-2020-media-release-fr.pdf [90] https://www.novartis.com/sites/www.novartis.com/files/2020-04-interim-financial-report-en.pdf [91] https://www.novartis.com/investors/financial-data/quarterly-results/2020-q1-transcript [92] https://www.novartis.com/sites/www.novartis.com/files/q1-2020-investor-presentation.mp3 [93] https://www.novartis.com/sites/www.novartis.com/files/q1-2020-investor-presentation.pdf [94] https://www.novartis.com/investors/environmental-social-and-governance/april-2020-update [95] https://www.novartis.com/sites/www.novartis.com/files/2020-03-avexis-investor-call-presentation.mp3 [96] https://www.novartis.com/sites/www.novartis.com/files/2020-03-avexis-investor-call-presentation.pdf [97] https://www.novartis.com/sites/www.novartis.com/files/q4-2019-media-release-en.pdf [98] https://www.novartis.com/sites/www.novartis.com/files/q4-2019-media-release-de.pdf [99] https://www.novartis.com/sites/www.novartis.com/files/q4-2019-media-release-fr.pdf [100] https://www.novartis.com/sites/www.novartis.com/files/2020-01-interim-financial-report-en.pdf [101] https://www.novartis.com/investors/financial-data/quarterly-results/2019-q4-and-full-year-results- transcript [102] https://www.novartis.com/sites/www.novartis.com/files/q4-2019-investor-presentation.mp3 [103] https://www.novartis.com/sites/www.novartis.com/files/q4-2019-investor-presentation.pdf [104] https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2019.pdf [105] https://www.novartis.com/investors/event-calendar/jp-morgan-healthcare-conference-2020- presentation-transcript [106] https://www.novartis.com/sites/www.novartis.com/files/2020-novartis-vas-narasimhan-jpmorgan- presentation.mp3 [107] https://www.novartis.com/sites/www.novartis.com/files/2020-novartis-vas-narasimhan-jpmorgan-q- a.mp3 [108] https://www.novartis.com/sites/www.novartis.com/files/2020-novartis-vas-narasimhan-jpmorgan- presentation.pdf [109] https://www.novartis.com/investors/event-calendar#tab-4 [110] https://www.novartis.com/news/media-releases/novartis-expects-sustain-long-term-growth-robust- pipeline-25-potential-blockbusters-highlighted-rd-day [111] https://www.novartis.com/sites/www.novartis.com/files/2019-r-d-day-investor-agenda.pdf [112] https://www.novartis.com/sites/www.novartis.com/files/2019-12-05-novartis-r-d-day-investor- presentation.pdf [113] https://www.novartis.com/news/media-releases/novartis-acquire-medicines-company-usd-97-bn- adding-inclisiran-potentially-transformational-investigational-cholesterol-lowering-therapy-address-leading- global [114] https://www.novartis.com/investors/event-calendar/novartis-enter-into-agreement-to-acquire-the- medicines-company [115] https://www.novartis.com/sites/www.novartis.com/files/novartis-agreement-acquire-medicines- company-investor-presentation.mp3 [116] https://www.novartis.com/sites/www.novartis.com/files/novartis-agreement-acquire-medicines- company-investor-presentation.pdf [117] https://www.novartis.com/sites/www.novartis.com/files/q3-2019-media-release-en.pdf [118] https://www.novartis.com/sites/www.novartis.com/files/q3-2019-media-release-de.pdf [119] https://www.novartis.com/sites/www.novartis.com/files/q3-2019-media-release-fr.pdf [120] https://www.novartis.com/sites/www.novartis.com/files/2019-10-interim-financial-report-en.pdf [121] https://www.novartis.com/investors/financial-data/quarterly-results/2019-q3-transcript [122] https://www.novartis.com/sites/www.novartis.com/files/q3-2019-ir-presentation.pdf [123] https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-beovu-offering-wet- amd-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept [124] https://www.novartis.com/sites/www.novartis.com/files/2019-10-novartis-beovu-fda-approval- investor-call-presentation.pdf [125] https://www.novartis.com/sites/www.novartis.com/files/2019-10-novartis-beovu-fda-approval- investor-call-presentation.mp3 [126] https://www.novartis.com/sites/www.novartis.com/files/2019-10-novartis-esmo-investor-call- presentation.mp3 [127] https://www.novartis.com/sites/www.novartis.com/files/2019-10-novartis-esmo-investor-call- presentation.pdf [128] https://www.novartis.com/sites/www.novartis.com/files/2019-09-novartis-ectrims-investor-call- presentation.mp3 [129] https://www.novartis.com/sites/www.novartis.com/files/2019-09-novartis-ectrims-investor-call- presentation.pdf [130] https://www.novartis.com/sites/www.novartis.com/files/2019-09-esg-presentation.mp3 [131] https://www.novartis.com/sites/www.novartis.com/files/2019-09-esg-presentation.pdf [132] https://www.novartis.com/sites/www.novartis.com/files/zolgensma-update-media-release-august- 2019.pdf [133] https://www.novartis.com/sites/www.novartis.com/files/zolgensma-update-recording.mp3 [134] https://www.novartis.com/sites/www.novartis.com/files/q2-2019-media-release-en.pdf [135] https://www.novartis.com/sites/www.novartis.com/files/q2-2019-media-release-de.pdf [136] https://www.novartis.com/sites/www.novartis.com/files/q2-2019-media-release-fr.pdf [137] https://www.novartis.com/sites/www.novartis.com/files/2019-07-interim-financial-report-en.pdf [138] https://www.novartis.com/investors/financial-data/quarterly-results/2019-q2-transcript [139] https://www.novartis.com/sites/www.novartis.com/files/q2-2019-ir-presentation.mp3 [140] https://www.novartis.com/sites/www.novartis.com/files/q2-2019-ir-presentation.pdf [141] https://www.novartis.com/sites/www.novartis.com/files/2019-06-novartis-asco-investor-event- presentation.pdf [142] https://www.novartis.com/news/media-releases/avexis-receives-fda-approval-zolgensma-first-and- only-gene-therapy-pediatric-patients-spinal-muscular-atrophy-sma [143] https://www.novartis.com/news/media-releases/avexis-announces-innovative-zolgensma-gene- therapy-access-programs-us-payers-and-families [144] https://www.avexis.com/content/pdf/prescribing_information.pdf [145] https://www.novartis.com/news/media-releases/fda-approves-novartis-piqray-first-and-only- treatment-specifically-patients-pik3ca-mutation-hrher2-advanced-breast-cancer [146] https://www.novartis.com/sites/www.novartis.com/files/2019-05-novartis-presentation-zolgensma- piqray-fda-approval.pdf [147] https://www.novartis.com/sites/www.novartis.com/files/2019-05-novartis-presentation-zolgensma- piqray-fda-approval.mp3 [148] https://www.novartis.com/news/media-releases/novartis-highlights-company-transformation-catalyst- rich-pipeline-and-strong-progress-strategy-meet-novartis-management-investor-event [149] https://www.novartis.com/sites/www.novartis.com/files/2019-05-meet-novartis-management- presentation.pdf [150] https://www.novartis.com/sites/www.novartis.com/files/2019-05-meet-the-management-agenda.pdf [151] https://www.novartis.com/news/media-releases/novartis-acquire-xiidra-expanding-front-eye-portfolio- and-strengthening-leadership-eye-care [152] https://www.novartis.com/sites/www.novartis.com/files/2019-05-novartis-xiidra-ir-call- presentation.mp3 [153] https://www.novartis.com/sites/www.novartis.com/files/2019-05-novartis-xiidra-ir-call-presentation.pdf [154] https://www.novartis.com/sites/www.novartis.com/files/2019-05-novartis-avexis-aan- presentation.mp3 [155] https://www.novartis.com/sites/www.novartis.com/files/2019-05-novartis-avexis-aan-presentation.pdf [156] https://www.novartis.com/sites/www.novartis.com/files/q1-2019-media-release-en.pdf [157] https://www.novartis.com/sites/www.novartis.com/files/q1-2019-media-release-de.pdf [158] https://www.novartis.com/sites/www.novartis.com/files/q1-2019-media-release-fr.pdf [159] https://www.novartis.com/sites/www.novartis.com/files/2019-04-interim-financial-report-en.pdf [160] https://www.novartis.com/investors/financial-data/quarterly-results/2019-q1-transcript [161] https://www.novartis.com/sites/www.novartis.com/files/q1-2019-ir-presentation.mp3 [162] https://www.novartis.com/sites/www.novartis.com/files/q1-2019-ir-presentation.pdf [163] https://www.novartis.com/sites/www.novartis.com/files/novartis-2017-2018-results-continuing- operations.pdf [164] https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-mayzent-siponimod- first-oral-drug-treat-secondary-progressive-ms-active-disease [165] https://www.novartis.com/sites/www.novartis.com/files/novartis-mayzent-fda-approval-investor- presentation.pdf [166] https://www.novartis.com/sites/www.novartis.com/files/novartis-mayzent-fda-approval-investor- presentation.mp3 [167] https://www.novartis.com/sites/www.novartis.com/files/alcon-20f-filing-2019.pdf [168] https://www.sec.gov/Archives/edgar/data/1167379/000104746919001507/0001047469-19-001507- index.htm [169] https://www.novartis.com/sites/www.novartis.com/files/q4-2018-media-release-en.pdf [170] https://www.novartis.com/sites/www.novartis.com/files/q4-2018-media-release-de.pdf [171] https://www.novartis.com/sites/www.novartis.com/files/q4-2018-media-release-fr.pdf [172] https://www.novartis.com/sites/www.novartis.com/files/2019-01-financial-report-en.pdf [173] https://www.novartis.com/investors/financial-data/quarterly-results/2018-q4-and-full-year-results- transcript [174] https://www.novartis.com/sites/www.novartis.com/files/q4-2018-ir-presentation.mp3 [175] https://www.novartis.com/sites/www.novartis.com/files/q4-2018-ir-presentation.pdf [176] https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2018-en.pdf [177] https://www.novartis.com/sites/www.novartis.com/files/2019-novartis-jpmorgan-presentation.pdf [178] https://www.novartis.com/investors/event-calendar#tab-5 [179] https://www.novartis.com/sites/www.novartis.com/files/2018-investors-alcon-cmd-agenda.pdf [180] https://www.novartis.com/sites/www.novartis.com/files/2018-investors-alcon-cmd-presentation- dec4.pdf [181] https://www.novartis.com/news/media-releases/alcon-highlight-its-vision-strategy-and-benefits- standalone-company-investors-and-analysts-new-york-and-london [182] https://www.novartis.com/sites/www.novartis.com/files/2018-investors-alcon-cmd-presentation.pdf [183] https://www.novartis.com/sites/www.novartis.com/files/novartis-financials-2015-2016-updated- segment-reporting.pdf [184] https://www.novartis.com/news/media-releases/novartis-rd-update-highlights-industry-leading- development-pipeline-including-potential-blockbusters-and-advanced-therapy-platforms [185] https://www.novartis.com/sites/www.novartis.com/files/2018-11-r-d-day-investor-agenda.pdf [186] https://www.novartis.com/sites/www.novartis.com/files/2018-11-05-r-d-day-investor-presentation.pdf [187] https://www.novartis.com/sites/www.novartis.com/files/2018-novartis-esmo-presentation.mp3 [188] https://www.novartis.com/sites/www.novartis.com/files/2018-novartis-esmo-presentation.pdf [189] https://www.novartis.com/sites/www.novartis.com/files/q3-2018-media-release-en.pdf [190] https://www.novartis.com/sites/www.novartis.com/files/q3-2018-media-release-de.pdf [191] https://www.novartis.com/sites/www.novartis.com/files/q3-2018-media-release-fr.pdf [192] https://www.novartis.com/sites/www.novartis.com/files/2018-10-interim-financial-report-en.pdf [193] https://www.novartis.com/investors/financial-data/quarterly-results/2018-q3-transcript [194] https://www.novartis.com/sites/www.novartis.com/files/q3-2018-ir-presentation.mp3 [195] https://www.novartis.com/sites/www.novartis.com/files/q3-2018-ir-presentation.pdf